Clinical trial
A Phase II Study Of Intravenous Edotecarin (PHA-782615) In Patients With Anthracycline- And Taxane Resistant Metastatic Breast Cancer
NCT00067314 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study Of Intravenous Edotecarin (PHA-782615) In Patients With Anthracycline- And Taxane Resistant Metastatic Breast Cancer
- Lead sponsor
- Pfizer
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 30, 2003
- Completion date
- June 30, 2007
- Enrollment
- 65
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.